Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, differentiated, and allogeneic human cell therapies. Lineage’s clinical and preclinical programs include five product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy being developed for the treatment of geographic atrophy under a worldwide collaboration with Roche and Genentech; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a for the treatment of spinal cord injury; (iii) VAC2, a dendritic cell therapy in Phase 1 for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for hearing loss treatment; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss.